HLA Loss of Heterozygosity
HLA LOH assay for patients with post-transplant relapse.
The HLA Loss of Heterozygosity Evaluation is intended for detecting and characterizing the presence or absence of genomic loss of heterozygosity in the HLA region for patients with post-transplant relapse. The HLA LOH assay starts with flow cytometric enrichment of relapsing cells, followed by genomic analysis using two different methods to ensure accurate detection of genomic loss.
labinfo@versiti.org
800-245-3117 x6250
Versiti’s HLA LOH evaluation detects genomic loss of heterozygosity and may indicate a loss of graft vs. leukemia effect, render treatments such as donor leukocyte infusion ineffective, and impact donor selection for future allogeneic HCT. Learn more about this assay and view Versiti’s abstract and poster presented at ASH’s annual meeting.